Skip to content

Metabolic Syndrome Feasibility Study

Prognostic Indicators for Metabolic Syndrome as Provided by the EPIC ClearView

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02287766
Acronym
EPIC-009
Enrollment
193
Registered
2014-11-11
Start date
2014-11-30
Completion date
2015-08-31
Last updated
2015-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Brief summary

The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with Metabolic Syndrome identified by medical doctors.

Interventions

None listed

Sponsors

Epic Research & Diagnostics, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
21 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

Metabolic Group Inclusion Criteria: 1. Sex: Male or Female 2. Age range: 21 to 85 3. Qualifying Metabolic Syndrome diagnosis(using the National Cholesterol Education Program Adult Treatment Panel (ATP) III definition)(Grundy, 2004) Subjects will be identified as having Metabolic Syndrome if they meet at least three of the following five criteria: * Elevated waist circumference: ≥ 102 cm (≥40 inches) in men, ≥ 88 cm (≥35 inches) in women * Elevated triglycerides: ≥ 150 mg/dL (1.7 mmol/L) or on drug treatment for elevated triglycerides (examples include, but are not limited to, fibrates and nicotinic acid) * Reduced HDL cholesterol: \< 40 mg/dL (1.03 mmol/L) in men or \< 50 mg/dL (1.3 mmol/L) in women or on drug treatment for reduced HDL-C * Elevated blood pressure: ≥ 130 mm Hg systolic blood pressure or ≥85 mm Hg diastolic blood pressure or on antihypertensive drug treatment in a patient with a history of hypertension * Elevated fasting glucose: ≥ 100 mg/dL or on drug treatment for elevated glucose 4. The patient or legal representative is able to understand and provide signed consent for the procedure.

Exclusion criteria

1. Patients \< 21years in age or \> 85 years in age. 2. Inability or unwillingness to provide informed consent. 3. Patients with pacemakers or another electrical device implanted somewhere in their body. 4. Pregnant women. 5. Missing all or part of fingers or cuts/burns on pads of fingers 6. Hand tremors or involuntary oscillations of the hands that prevents clear imaging Control Group: Inclusion Criteria: 1. Sex: Male or Female 2. Age range: 21 to 85 3. Freedom from qualifying medical diagnoses (control group) Any one of the following will exclude the subject from participation in the study 1. Documented current diagnosis/treatment of cancer (including Sickle Cell Disease) 2. Documented current diagnosis/treatment of coronary artery disease or heart attack 3. Documented as currently in Renal Failure (chronic or acute) or on renal dialysis 4. Documented current diagnosis/treatment for Hepatitis 5 .The patient or legal representative is able to understand and provide signed consent for the procedure.

Design outcomes

Primary

MeasureTime frameDescription
Agreement of ClearView Scan versus Active DiagnosisAt time of ClearView Scan (Single study visit only, with no follow-up. The study endpoint will be reported for day 0, the day of the study visitThe EPIC ClearView software produces a Response Scale report that summarizes the electrophysiological measurements associated with organ systems. The autonomic numbers indicate how the person's stress response is affecting different body systems and the physical numbers reflect physiological function.These measurements will then be compared to metabolic diagnosis.

Secondary

MeasureTime frame
Sensitivity and Specificity of ClearView Scan versus Active DiagnosisSingle study visit only, with no follow-up. The study endpoint will be reported for day 0, the day of the study visit

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026